Press Release: "Leading Industry Sales Professional Joins the Executive Team at Antidote"
NEW YORK, NY (June 24, 2019) - Antidote Technologies is pleased to announce the newest member of the team: VP of Business Development, Kathy Freeman.
Kathy brings 20 years of strategic alliance management experience in the clinical trials space, with a focus on developing partnerships to encourage a patient-first approach to clinical trial recruitment. She most recently served as Senior Director of Business Development at QPS Holdings.
Kathy will join the executive management team at Antidote and lend her extensive experience to help shape the overall long-term strategic direction and success of the company.
“We’ve set ambitious goals for the company, and we’ve been looking for just the right person to drive Antidote’s sales efforts as we scale,” said Laurent Schockmel, CEO. “Kathy’s experience and dedication to our mission will be invaluable as we work to truly transform the way that patients connect with medical research.”
“I’ve worked in this industry for decades, honing my passion for putting patients first in clinical trial outreach and enrollment,” said Kathy. “This is what Antidote does best, and I’m honored to be a part of the team.”
Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote uses precision recruitment to match the right patients with the right trials. Antidote strikes the right balance between technology and human touch to deliver high-quality patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit www.antidote.me.